Topical Calcipotriol Plus 5-Fluorouracil Immunotherapy for Actinic Keratosis Treatment
Marjan Azin, Andrew B. Mahon, Steven Isaacman, Julia E. Seaman, Isabel Elaine Allen, Michael Szarek, Lynn A. Cornelius, Shadmehr Demehri
Abstract
Actinic keratosis (AK) is a precursor to cutaneous squamous cell carcinoma. Lengthy treatment duration and severe side effects have limited the therapeutic efficacy of the Food and Drug Administration–approved topical AK treatments (Cornejo et al., 2020). In addition, the efficacy of these treatments against hypertrophic AK is unclear. We previously showed the high efficacy of topical calcipotriol (a low-calcemic vitamin D3 analog) in combination with 5-fluorouracil (5-FU, an established topical AK treatment) for the elimination of AK in patients with multiple AKs at baseline in a randomized, double-blind clinical trial (Cunningham et al., 2017).